A Systematic Review of the Use of Rituximab for Desensitization in Renal Transplantation
Authors:
- Philip S. MacklinPMPhilip S. Macklin
- Peter J. MorrisPMPeter J. Morris
- Simon R. KnightSKSimon R. Knight
- 27 October 2014
- journal article
- review article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 98 (8) , 794-805
Abstract
Rituximab is a B lymphocyte-depleting agent used to treat lymphoma and autoimmune diseases. Recently, it has been used for desensitization therapy in ABO-incompatible and highly sensitized recipients undergoing renal transplantation. A systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Four databases and three trial registries were searched for studies comparing rituximab with non-rituximab desensitization protocols. A lack of randomized evidence precluded meta-analysis, and thus a narrative review was conducted. Forty-five records met the inclusion criteria, relating to 21 individual studies (two randomized controlled trials and 19 retrospective cohort studies). Ten studies investigated the use of rituximab in ABO-incompatible patients; most found no significant differences in patient and graft outcomes when compared most frequently to splenectomy-based protocols. Nine studies of limited quality focused on highly sensitized recipients (positive cross-match, donor-specific antibody, and elevated panel reactive antibody) and demonstrated some benefits in graft survival, acute and chronic rejection, and sensitization levels with rituximab. The remaining two studies combined ABO-incompatible and highly sensitized recipients and found no statistically significant increase in infectious complications with rituximab. Evidence of limited quality was identified to support the use of rituximab desensitization in highly sensitized recipients. Among ABO-incompatible recipients, rituximab was found to be equivalent to splenectomy, indicating that this invasive surgical procedure is not necessary. Further randomized controlled trials are required to better define the efficacy, long-term safety, and optimal dosing regimen of rituximab in this setting.Keywords
This publication has 65 references indexed in Scilit:
- Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patientsAnnals of the Rheumatic Diseases, 2013
- Impact of pretransplant rituximab induction on highly sensitized kidney recipients: comparison with non-rituximab groupJournal of the Korean Surgical Society, 2012
- Infectious Complications in Kidney-Transplant Recipients Desensitized with Rituximab and Intravenous ImmunoglobulinClinical Journal of the American Society of Nephrology, 2011
- Chronic Antibody-Mediated Rejection Is Reduced by Targeting B-Cell Immunity During an Introductory PeriodAmerican Journal of Transplantation, 2011
- The 5-Year Outcome of ABO-Incompatible Kidney Transplantation With Rituximab InductionTransplantation, 2011
- Incidence of Infectious Complications in Highly Sensitized Renal Transplant Recipients Treated by Rituximab: A Case-Controlled StudyTransplantation, 2010
- Evaluation of Low-Dose Rituximab Induction Therapy in Living Related Kidney TransplantationTransplantation, 2010
- A Randomized, Prospective Trial of Rituximab for Acute Rejection in Pediatric Renal TransplantationAmerican Journal of Transplantation, 2008
- Excellent Long-term Outcome of ABO-Incompatible Living Donor Kidney Transplantation in JapanAmerican Journal of Transplantation, 2004
- The Quality of Life of Patients with End-Stage Renal DiseaseNew England Journal of Medicine, 1985